<div id="readability-page-1"><div>         <div>                                                                  <p>,  /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced the successful completion of cohort 1 dosing in a phase I clinical trial for a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP).</p> <p>HXN-1011 is a novel recombinant humanized biparatopic antibody directed against two distinct epitopes on TSLP. The antibody binds TSLP with high affinity and simultaneously blocks its interaction to both units of the heterodimeric TSLP receptor, the TSLPR (also known as CRLF2) and the interleukin 7 receptor alpha (IL7Ra). In preclinical studies, HXN-1011 has demonstrated more potent activity, along with a long-lasting pharmacodynamic effect, in multiple <i>in vitro</i> assays and animal models compared to several benchmark products currently under clinical development. HXN-1011 is formulated at high protein concentration for subcutaneous injection.</p> <p>&#34;TSLP has emerged as an attractive therapeutic target in the treatment of a variety of human immunological disorders, including asthma, atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.&#34; Zhenping Zhu, MD, PhD, President &amp; Co-CEO of Earendil Labs, commented, &#34;HXN-1011 represents a highly differentiated next-generation TSLP antagonist with the best-in-class potential in the field. We are working diligently to advance HXN-1011 clinical programs globally to develop innovative treatments for patients in need.&#34;</p> <p>Jian Peng, PhD, CEO of Earendil Labs, stated, &#34;Our team has demonstrated remarkable speed and discipline in advancing HXN-1011 from discovery to clinical stage. We are fully committed to developing next-generation biologics therapies for patients suffering from underserved autoimmune and inflammatory diseases.&#34;</p> <p><b>About Earendil Lab<span id="spanHghlt8f04">s:</span></b> Earendil Labs is an AI-powered biotechnology company advancing next-generation biologics for patients with autoimmune diseases, cancer, and other areas of significant unmet medical need. By integrating artificial intelligence across the full R&amp;D lifecycle, Earendil Labs and its affiliate Helixon Therapeutics have been building a scalable engine to systematically generate and advance high-quality therapeutic programs.</p> <p>The company's AI-native approach enables efficient creation, optimization, and progression of protein-based biologics with the potential to be first-in-class and best-in-class, translating computational innovation into real clinical and patient impact. Through a combination of internal pipeline development and strategic partnerships, Earendil Labs aims to deliver transformative medicines to patients worldwide.</p> <p>SOURCE Earendil Labs</p> <p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9Q042MTUxOCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgwNzAwUFJfTkVXU19VU1BSX19fX19DTjYxNTE4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9Q042MTUxOCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgwNzAwUFJfTkVXU19VU1BSX19fX19DTjYxNTE4"/></p></div>       </div></div>

02268

WXXWY

02269

<p>Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.</p>

prnewswire

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

iShares US Pharma

China Southern Hang Seng Biotech ETF(QDII)

Ark Genomic Revolution ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

SPDR S&P Biotech

Minsheng Royal CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

iShares Biotechnology ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Guotai CSI Bio-medicine ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)